Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $125.2857.
BLLN has been the subject of a number of analyst reports. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, May 15th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Guggenheim raised their price target on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. BTIG Research decreased their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. lifted their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th.
Get Our Latest Research Report on BLLN
Institutional Inflows and Outflows
Billiontoone Stock Up 1.2%
BLLN stock opened at $98.99 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The company has a 50 day moving average of $83.46. The company has a market capitalization of $4.55 billion and a P/E ratio of 179.98. Billiontoone has a twelve month low of $61.96 and a twelve month high of $138.70.
Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. The firm’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.39) earnings per share. On average, equities research analysts anticipate that Billiontoone will post 0.93 EPS for the current fiscal year.
About Billiontoone
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Featured Articles
- Five stocks we like better than Billiontoone
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
